Role of cyclooxygenase-2 in pathogenesis and prevention of colorectal cancer

Digestive Diseases

Volumn 28, Issue 4-5, 2010, Pages 585-589

  Hahn, Ezra ^a   Kraus, Sarah ^b,c   Arber, Nadir ^b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Chemoprevention; Colorectal cancer; Cyclooxygenase 2; Nonsteroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2; EFLORNITHINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIROXICAM; ROFECOXIB; SULINDAC;

ADENOMATOUS POLYP; ANGIOGENESIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PREVENTION; CANCER RISK; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; CONFERENCE PAPER; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUSTRY; DRUG SAFETY; EMBRYO DEVELOPMENT; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART FAILURE; HEART INFARCTION; HUMAN; IMMUNOREGULATION; INFLAMMATION; LOW DRUG DOSE; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PATIENT SELECTION; PRIORITY JOURNAL; STROKE; TREATMENT DURATION; WOUND HEALING;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; HUMANS; INDIVIDUALIZED MEDICINE;

EID: 78649389948     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000320278     Document Type: Conference Paper

References (37)

1. World Health Organization: Cancer. http:// www.who.int/mediacentre/ factsheets/fs297/ en/index.html (accessed July 16, 2010).
2. Weir HK, Thun MJ, Hankey BF, et al: Annua l report to t he nation on the status of cancer, 1975-2000, featuring the use of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95:1276-1299.
3. Arber N: Cyclooxygenase-2 inhibitors in colorectal cancer prevention: point. Cancer Epidemiol Biomarkers Prev 2008; 17: 18 52-1857.
4. Takayama T, Goji T, Taniguchi T, Inoue A: Chemoprevention of colorectal cancer - experimental and clinical aspects. J Med Invest 2009; 56: 1-5.
5. Kraus S, Arber N: Colorectal cancer chemo-prevention: ready for practice? Eur J Cancer 2009; 45(suppl 1):360-366.
6. Tuynman JB, Peppelenbosch MP, Richel DJ: COX-2 inhibition as a tool to treat and prevent colon cancer. Crit Rev Oncol Hematol 2004; 52: 81-101.
7. Chandrasekharan N V, Dai H, Roos KL, et al: COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 13926-13931.
8. Half E, Arber N: Colon cancer: preventive agents and the present status of chemopre-vention. Expert Opin Pharmacother 2009; 10:211-219.
9. Eberhart CE, Coffey RJ, Radhika A, et al: Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and ad-enocarcinomas. Gastroenterology 1994; 107: 1183-1188.
10. Bennett A, Del Tacca M: Proceedings: pros-taglandins in human colonic carcinoma. Gut 1975; 16:409.
11. Cryer B: NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality. Am J Gastroenterol 2005; 100:1694-1695.
12. Grover JK, Yadav S, Vats V, Joshi YK: Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. Int J Colorectal Dis 2003; 18 : 279-291.
13. FitzGerald Ga, Patrono C: The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345:433-42.
14. DuBois RN, Radhika A, Reddy BS, et al: Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroen-terology 1996; 110 : 1259-1262.
15. Shiff SJ, Rigas B: The role of cyclooxygen-ase inhibition in the antineoplasic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 1999; 190: 445-450.
16. Hao X P, Bishop AE, Wallace MH, et al: Early expression of cyclooxygenase-2 during sporadic colorectal carcinogenesis. J Pathol 1999; 18 7: 295-301.
17. Oshima M, Murai N, Kargman S, et al: Che-moprevention of intestinal polyposis in the Apcdelta716 mouse by rofecoxib, a specific cyclooxygenase-2 inhibitor. Cancer Res 2001; 61:1733-1740.
18. Steinbach G, Lynch P, Phillips RK, et al: The ef fect of celecox ib, a c ycloox ygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 20 00; 342: 194 6 -1952.
19. Arber N, Eagle CJ, Spicak J, et al: Celecoxib for the prevention of colorectal adenomatous poly ps. N Engl J Med 2006; 355: 885-895.
20. Bertagnolli MM, Eagle CJ, Zauber AG, et al: Celecoxib for the prevention of sporadic colorectal adenomas. N Eng l J Med 20 06; 355: 873-884.
21. Baron JA, Sandler RS, Bresalier RS, et al: A randomized trial of rofecoxib for the chemo-prevention of colorectal adenomas. Gastro-enterolog y 2006; 131: 16 74-16 82.
22. Bresalier RS, Sandler RS, Quan H, et al: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102.
23. Solomon SD, McMurray JJ, Pfeffer MA, et al: Cardiovascular risk associated with celeco-xib in a clinical trial for colorectal adenoma prevention. N Engl J Med 20 05; 352: 1071-1080.
24. Hawk E, Vinder JL: The adenoma prevention with celecoxib and prevention of colorectal sporadic adenomatous polyps trials: stepping stones to progress. Cancer Epidemiol Biomarkers Prev 2007; 15: 185-187.
25. Bertagnolli MM: Chemoprevention of colo-rectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol 2007; 8:439-443.
26. Rao CV, Reddy BS: NSAIDs and chemopre-vention. Curr Cancer Drug Targets 2004; 4: 29-42.
27. Sinicrope FA: Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog 20 06; 45: 447-454.
28. Arber N, Levin B: Chemoprevention of colorectal neoplasia; the potential for personalized medicine. Gastroenterology 2008; 134: 1224-1237.
29. Grover JK, Yadav S, Vats V, Joshi YK: Cyclo-oxygenase 2 inhibitors: emerging roles in the gut. Int J Colorectal Dis 2003; 18 : 279-291.
30. Chan AT, Ogino S, Fuchs CS: Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med 2007; 356: 2131-2142.
31. Ulrich CM, Bigler J, Potter JD: Non-steroidal ant-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-140.
32. Bigler J, Whitton J, Lampe JW, et al: CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res 2001; 61: 3566-3569.
33. Macarthur M, Sharp L, Hold GL, Little J, El-Omar EM: The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev 2005; 14:1613-1618.
34. Lin HJ, Lakkides KM, Keku TO, et al: Pros-taglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev 2002; 11 : 1305-1315.
35. Agarwal B, Rao CV, Bhendwal S, et al: Lov-astatin augments sulindac-induced apopto-sis in colon cancer cells and potentiates chemopreventive effects of sulindac. Gas-troenterolog y 1999; 117: 838-847.
36. Reddy BS, Wang CX, Kong AN, et al: Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 20 06; 66: 454 2- 454 6.
37. Jacoby RF, Cole CE, Hawk ET, et al: Ursode-oxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology 2004; 127: 838-844.